Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
WM Zhu, MR Middleton - Immunotherapy Advances, 2023 - academic.oup.com
Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells
expressing tumour-associated antigens to induce tumour cell killing. This inherently relies …
expressing tumour-associated antigens to induce tumour cell killing. This inherently relies …
Ponatinib‐review of historical development, current status, and future research
HM Kantarjian, HT Chifotides… - American journal of …, 2024 - Wiley Online Library
Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …
[HTML][HTML] Ponatinib vs. Imatinib as frontline treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia: a matching adjusted indirect comparison
JM Ribera, T Prawitz, A Freitag, A Sharma, B Dobi… - Advances in …, 2023 - Springer
Introduction Efficacy of ponatinib-based treatment for patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has not been compared to …
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has not been compared to …
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
D Hoelzer, R Bassan, N Boissel, C Roddie… - Annals of …, 2024 - annalsofoncology.org
The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step
forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will …
forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will …
Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia
LC Zarling, PA Stevenson, LA Soma… - European Journal of …, 2023 - Wiley Online Library
Objectives We recently performed a single‐arm phase II trial of DA‐EPOCH in adults with
acute lymphoblastic leukemia (ALL). We sought to compare these results to those with …
acute lymphoblastic leukemia (ALL). We sought to compare these results to those with …
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era
T Badar, H Alkhateeb, M Aljurf… - Current Research in …, 2023 - Elsevier
Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was dismal. The TKI …
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was dismal. The TKI …
[HTML][HTML] Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts
Simple Summary Acute lymphoblastic leukemia is a malignant disease which is commonly
treated with various chemotherapeutic drugs. Novel therapeutic options are gaining interest …
treated with various chemotherapeutic drugs. Novel therapeutic options are gaining interest …
Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens
NJ Short, H Kantarjian, E Jabbour - Leukemia & Lymphoma, 2024 - Taylor & Francis
Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-
cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional …
cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional …
Celebrating a year of cancer research in Blood Advances
CM Bollard, A Weyrich - Blood Advances, 2023 - ashpublications.org
With the close of 2023, we wanted to take stock of the seventh year for Blood Advances. It
has been another superb year for the journal, receiving a large number of submissions …
has been another superb year for the journal, receiving a large number of submissions …
A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
ZY Xiong, YJ Shen, SZ Zhang, HH Zhu - Hematology, 2024 - Taylor & Francis
Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) is the most
common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis …
common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis …